Instituto Bioclon
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trails to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Instituto Bioclon
The Instituto Bioclon S.A. de C.V. (Bioclon Institute) was formed in 1990 to research and develop F(ab’)2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize ANAVIP becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trails to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.
has abstract
The Instituto Bioclon S.A. de ...... ack widow spider envenomation.
@en
founding year
industry
service
Link from a Wikipage to an external page
Wikipage page ID
31,926,273
page length (characters) of wiki page
Wikipage revision ID
974,520,473
Link from a Wikipage to another Wikipage
foundation
industry
location city
location country
name
Instituto Bioclon S.A. de C.V.
@en
parent
Silanes Laboratories
@en
services
Antivenom research and development
@en
type
Private
@en
wikiPageUsesTemplate
comment
The Instituto Bioclon S.A. de ...... ack widow spider envenomation.
@en
label
Instituto Bioclon
@en
wasDerivedFrom
isPrimaryTopicOf
name
Instituto Bioclon S.A. de C.V.
@en